AtCor sends investors' pulses racing

AtCor's full-year guidance was strong and is encouraging for the blood pressure medical device maker's future.

AtCor Medical (ACG) share price enjoyed its second best one-day surge on record after it confirmed that it will report a maiden full year profit when it releases its results next month.

AtCor, which developed a blood pressure and arterial stiffness measuring device, said 2012-13 sales is expected to surge 40% to $9 million and full year profit will range between $2.7 million to $2.9 million.

This would put the stock on a very modest price-earnings multiple of under four times based on its last traded share price before the news, although the result was bolstered by a one-off research and development tax credit of $700,000 from the federal government.

However, its operating result is still encouraging as the company recorded a cash flow from operations of $600,000 for the period.

AtCor’s cash position is $2.9 million, which is more than double what it held in the bank a year ago.

But investors wouldn't be too surprised at the strong result if they had read Three small cap pocket rockets back in February.

The stock, which is not part of the Uncapped 100, jumped 43.8% to 10.5 cents in early trade. If it closes at this level, it would mark the stock’s best one-day jump since 2007.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles